Results for tag: "Pirfenidone"

Pirfenidone is a drug used to treat idiopathic pulmonary fibrosis (IPF), a chronic, progressive lung disease. It is the only approved drug for IPF in the United States and Europe, and is also approved in Japan, Canada, and other countries. Pirfenidone works by reducing inflammation and scarring in the lungs, slowing the progression of the disease. It is usually taken orally, three times a day. Pirfenidone is a relatively new drug, and the market is still developing. It is expected to grow in the coming years, as more people are diagnosed with IPF and the drug is increasingly prescribed. The drug is also being studied for other respiratory diseases, such as chronic obstructive pulmonary disease (COPD). Companies in the Pirfenidone market include InterMune, Inc., which developed the drug, and Roche, which acquired InterMune in 2014. Other companies include Shionogi & Co., Ltd., which markets the drug in Japan, and Mylan, which markets a generic version of the drug in the United States. Show Less Read more